세계의 급성 세균성 피부 및 피부 구조 감염증(ABSSSI) 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

The forecast for the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment market predicts substantial growth, with market size projected to soar to USD 2.73 Billion by 2033, a significant increase from the USD 1.71 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 5.32% anticipated between 2025 and 2033.

The ABSSSI treatment market is poised for growth driven by rising incidence of bacterial infections and increasing antibiotic resistance challenges. Novel antimicrobial agents, including lipoglycopeptides, oxazolidinones, and beta-lactamase inhibitors, are expanding therapeutic options with improved efficacy and safety profiles. Future developments will focus on targeted therapies, combination regimens, and rapid diagnostic tools to optimize treatment outcomes and reduce hospital stays.

Moreover, the integration of antimicrobial stewardship programs and personalized medicine approaches is enhancing clinical decision-making. The growing prevalence of comorbidities such as diabetes and obesity is increasing patient susceptibility, driving demand for effective ABSSSI treatments. Advances in drug delivery systems, including topical and long-acting formulations, are improving patient compliance. As healthcare systems combat resistant pathogens, the ABSSSI treatment market will continue to innovate, delivering advanced therapies that address unmet clinical needs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Infection Type

• Community-Acquired ABSSSI
• Hospital-Acquired ABSSSI

By Drug Class

• Glycopeptides/Lipoglycopeptides
• Oxazolidinones
• Beta-lactams
• Lipopeptide
• Tetracyclines
• Other Drug Classes

By Route of Administration

• Parenteral
• Oral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• List of Companies Profiled in the report
• AbbVie, Basilea Pharmaceutica, Cipher Pharmaceuticals, Endo Pharmaceuticals, Glenmark Pharmaceuticals, Melinta Therapeutics, Menarini Group, Merck, Nabriva Therapeutics, Paratek Pharmaceuticals, Pfizer, Sandoz

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Infection Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET ANALYSIS BY INFECTION TYPE

• 5.1. Overview By Infection Type
• 5.2. Historical and Forecast Data Analysis By Infection Type
• 5.3. Community-acquired ABSSSI Historic and Forecast Sales By Regions
• 5.4. Hospital-acquired ABSSSI Historic and Forecast Sales By Regions

6. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Glycopeptides/Lipoglycopeptides Historic and Forecast Sales By Regions
• 6.4. Oxazolidinones Historic and Forecast Sales By Regions
• 6.5. Beta-lactams Historic and Forecast Sales By Regions
• 6.6. Lipopeptide Historic and Forecast Sales By Regions
• 6.7. Tetracyclines Historic and Forecast Sales By Regions
• 6.8. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data Analysis By Route of Administration
• 7.3. Parenteral Historic and Forecast Sales By Regions
• 7.4. Oral Historic and Forecast Sales By Regions
• 7.5. Topical Historic and Forecast Sales By Regions

8. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 8.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 8.5. Online Pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT COMPANIES

• 10.1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Basilea Pharmaceutica
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Cipher Pharmaceuticals
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Endo Pharmaceuticals
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Glenmark Pharmaceuticals
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Melinta Therapeutics
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Menarini Group
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Merck
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Nabriva Therapeutics
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Paratek Pharmaceuticals
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Pfizer
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Sandoz
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies